Target Name: ZNF219
NCBI ID: G51222
Review Report on ZNF219 Target / Biomarker Content of Review Report on ZNF219 Target / Biomarker
ZNF219
Other Name(s): ZNF219 variant 3 | ZFP219 | Zinc finger protein 219 | Zinc finger protein 219, transcript variant 3 | ZNF219 variant 2 | ZN219_HUMAN | Zinc finger protein 219, transcript variant 2 | Zinc finger protein 219, transcript variant 1 | zinc finger protein 219 | ZNF219 variant 1

ZNF219: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Psychiatric Disorders

ZNF219 (ZNF219 variant 3) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. ZNF219 is a non-coding RNA molecule that is part of the ZNF2 complex, a protein complex that is involved in a variety of cellular processes, including cell growth, differentiation, and inflammation.

The ZNF2 complex consists of at least four subunits, including ZNF211, ZNF212, ZNF213, and ZNF214, which are involved in regulating various cellular processes, including cell growth, differentiation, and inflammation. ZNF219 is a variant of the ZNF2 gene that has been identified as a potential drug target or biomarker.

One of the unique features of ZNF219 is its role in the regulation of T-cell development and function. T-cells are a type of white blood cell that play a critical role in the immune system, and they are involved in the development and destruction of many diseases, including cancer. ZNF219 has been shown to be involved in the regulation of T-cell development and function, including the development of T-cells from stem cells and the regulation of T-cell proliferation.

In addition to its role in T-cell development and function, ZNF219 has also been shown to be involved in the regulation of neurodegenerative diseases. Neurodegenerative diseases are a group of diseases that are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the degenerative effects of these diseases. ZNF219 has been shown to be involved in the regulation of neurodegenerative diseases, including the progressive neurodegeneration that is observed in diseases such as Alzheimer's and Parkinson's.

Furthermore, ZNF219 has also been shown to be involved in the regulation of psychiatric disorders. psychiatric disorders are a group of conditions that are characterized by the presence of symptoms such as anxiety, depression, and psychosis. ZNF219 has been shown to be involved in the regulation of psychiatric disorders, including the development and progression of psychiatric disorders.

In conclusion, ZNF219 is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. ZNF219 is involved in the regulation of T-cell development and function, neurodegenerative diseases, and psychiatric disorders. Further research is needed to fully understand the role of ZNF219 in these diseases and to develop effective treatments.

Protein Name: Zinc Finger Protein 219

Functions: Transcriptional regulator (PubMed:14621294, PubMed:19549071). Recognizes and binds 2 copies of the core DNA sequence motif 5'-GGGGG-3' (PubMed:14621294). Binds to the HMGN1 promoter and may repress HMGN1 expression (PubMed:14621294). Regulates SNCA expression in primary cortical neurons (PubMed:19549071). Binds to the COL2A1 promoter and activates COL2A1 expression, as part of a complex with SOX9 (By similarity). Plays a role in chondrocyte differentiation (By similarity)

The "ZNF219 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF219 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256 | ZNF257 | ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267 | ZNF268 | ZNF271P | ZNF273 | ZNF274 | ZNF275 | ZNF276 | ZNF277 | ZNF28 | ZNF280A | ZNF280B | ZNF280C | ZNF280D | ZNF281 | ZNF282 | ZNF283 | ZNF284 | ZNF285 | ZNF285CP | ZNF286A | ZNF286B | ZNF287 | ZNF292 | ZNF295-AS1 | ZNF296 | ZNF3 | ZNF30 | ZNF300 | ZNF300P1 | ZNF302 | ZNF304 | ZNF311 | ZNF316 | ZNF317 | ZNF318 | ZNF319 | ZNF32 | ZNF32-AS1 | ZNF32-AS2 | ZNF32-AS3 | ZNF320 | ZNF321P | ZNF322 | ZNF322P1 | ZNF324 | ZNF324B | ZNF326 | ZNF329 | ZNF330 | ZNF331 | ZNF333 | ZNF334 | ZNF335 | ZNF337 | ZNF33A | ZNF33B | ZNF33BP1 | ZNF34 | ZNF341 | ZNF341-AS1 | ZNF343 | ZNF345 | ZNF346